^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    BIOMARKER:

    RAD51B mutation

    i
    Entrez ID:
    5890
    Related biomarkers:
    CNA
    Others
    Related tests:
    Apply
    A Phase I/II Study of Sacituzumab Govitecan Plus Berzosertib in Small Cell Lung Cancer, Extra-Pulmonary Small Cell Neuroendocrine Cancer and Homologous Recombination-Deficient Cancers Resistant to PARP Inhibitors (NCT04826341)
    Phase 1/2
    National Cancer Institute (NCI)
    Recruiting
    Last update posted :
    02/21/2025
    Initiation :
    09/20/2021
    Primary completion :
    03/01/2026
    Completion :
    03/01/2027
    BRCA1 • BRCA2 • HRD • CDK12 • BRCA • CHEK2 • RAD51B • BRIP1 • RAD51C • RAD51D • CHEK1 • BARD1 • RAD54L • FANCL • PPP2R2A
    |
    ATM mutation • PALB2 mutation • CDK12 mutation • CHEK2 mutation • BRIP1 mutation • RAD51C mutation • RAD51D mutation • RAD51B mutation • BARD1 mutation • CHEK1 mutation • RAD54L mutation
    |
    berzosertib (M6620) • Trodelvy (sacituzumab govitecan-hziy)
    Studying the Safety and Determining the Optimal Dose of Novobiocin in Patients With Tumors That Have Alterations in DNA Repair Genes (NCT05687110)
    Phase 1
    National Cancer Institute (NCI)
    Recruiting
    Last update posted :
    02/04/2025
    Initiation :
    07/06/2023
    Primary completion :
    08/01/2026
    Completion :
    09/01/2026
    BRCA1 • BRCA2 • CDK12 • FANCA • RAD51B • BRIP1 • RAD51C • RAD50 • RAD51D • BARD1 • NBN • FANCF • FANCM • FANCD2 • FANCE • FANCC
    |
    ATM mutation • PALB2 mutation • CDK12 mutation • BRIP1 mutation • RAD51C mutation • RAD51D mutation • RAD51B mutation • BARD1 mutation
    Pembrolizumab, Olaparib, and Temozolomide for People with Glioma (NCT05188508)
    Phase 2
    Memorial Sloan Kettering Cancer Center
    Recruiting
    Last update posted :
    02/03/2025
    Initiation :
    01/14/2022
    Primary completion :
    01/01/2026
    Completion :
    01/01/2026
    EGFR • BRCA1 • BRCA2 • HRD • CDKN2A • FGFR • CDK12 • CDKN2B • CHEK2 • RAD51B • BRIP1 • RAD51C • RAD51D • CHEK1 • BARD1 • RAD54L • FANCL • PPP2R2A
    |
    CDKN2A deletion • BRIP1 mutation • RAD51C mutation • RAD51B mutation • BARD1 mutation • IDH wild-type
    |
    Keytruda (pembrolizumab) • Lynparza (olaparib) • temozolomide
    Niraparib in Tumors Metastatic to the CNS (NCT04992013)
    Phase 2
    Massachusetts General Hospital
    Recruiting
    Last update posted :
    12/12/2024
    Initiation :
    04/05/2022
    Primary completion :
    12/01/2025
    Completion :
    06/01/2027
    BRCA1 • BRCA2 • HRD • BAP1 • RAD51B • BRIP1 • RAD51C • RAD50 • PARP1 • BARD1 • NBN • RAD54L • XRCC2 • RAD54B • XRCC3
    |
    HRD • ATM mutation • PALB2 mutation • BRIP1 mutation • RAD51C mutation • RAD51D mutation • RAD51B mutation • BARD1 mutation • RAD54L mutation
    |
    Zejula (niraparib)
    Olaparib in Men With High-Risk Biochemically-Recurrent Prostate Cancer Following Radical Prostatectomy, With Integrated Biomarker Analysis (NCT03047135)
    Phase 2
    Sidney Kimmel Comprehensive Cancer Center at Jo...
    Active, not recruiting
    Last update posted :
    07/03/2024
    Initiation :
    03/01/2017
    Primary completion :
    05/24/2023
    Completion :
    05/01/2025
    BRCA1 • BRCA2 • ATM • CDK12 • CHEK2 • RAD51B • BRIP1 • RAD51C • RAD51D • CHEK1 • BARD1 • FANCL • PPP2R2A
    |
    BRCA1 mutation • ATM mutation • PALB2 mutation • CDK12 mutation • CHEK2 mutation • BRIP1 mutation • RAD51C mutation • RAD51D mutation • RAD51B mutation • BARD1 mutation • CHEK1 mutation • CHEK1 expression
    |
    Lynparza (olaparib)
    Study of Olaparib in Metastatic Renal Cell Carcinoma Patients With DNA Repair Gene Mutations (ORCHID) (NCT03786796)
    Phase 2
    Sidney Kimmel Comprehensive Cancer Center at Jo...
    Recruiting
    Last update posted :
    03/05/2024
    Initiation :
    06/03/2019
    Primary completion :
    03/01/2025
    Completion :
    03/01/2026
    BRCA1 • BRCA2 • BAP1 • CDK12 • CHEK2 • RAD51B • BRIP1 • RAD51C • RAD51D • CHEK1 • BARD1 • RAD54L • FANCL
    |
    ATM mutation • PALB2 mutation • CDK12 mutation • CHEK2 mutation • BRIP1 mutation • RAD51C mutation • RAD51D mutation • RAD51B mutation • BARD1 mutation • CHEK1 mutation • RAD54L mutation
    |
    Lynparza (olaparib)
    A Study of Olaparib Prior to Surgery and Chemotherapy in Ovarian, Primary Peritoneal, and Fallopian Tube Cancer (NEO) (NCT02489006)
    Phase 2
    University Health Network, Toronto
    Active, not recruiting
    Last update posted :
    01/17/2024
    Initiation :
    07/19/2016
    Primary completion :
    12/31/2025
    Completion :
    12/31/2025
    BRCA1 • BRCA2 • PALB2 • RAD51B • BRIP1 • RAD51C • PARP1 • RAD51D • BARD1 • PPM1D • FANCM
    |
    PALB2 mutation • BRIP1 mutation • RAD51C mutation • RAD51D mutation • RAD51B mutation • BARD1 mutation
    |
    Lynparza (olaparib)
    Olaparib and Bevacizumab in Relapsed Small Cell Lung Cancer Subjects (SUKSES-B2) (NCT04939662)
    Phase 2
    Se-Hoon Lee
    Completed
    Last update posted :
    01/01/2024
    Initiation :
    06/11/2021
    Primary completion :
    10/27/2023
    Completion :
    10/27/2023
    BRCA1 • BRCA2 • SLFN11 • BRCA • RAD51 • RAD51B • RAD51C • RAD50 • NBN • RAD54L • WRN • POU2F3 • RAD52 • RECQL5 • RECQL • RECQL4 • RPA1
    |
    RAD51C mutation • RAD51D mutation • RAD51B mutation • BRCA mutation • RAD54L mutation
    |
    Avastin (bevacizumab) • Lynparza (olaparib)
    Niraparib and Dostarlimab in HRD Solid Tumors (DIDO) (NCT04983745)
    Phase 2
    West Cancer Center
    Recruiting
    Last update posted :
    12/21/2023
    Initiation :
    11/29/2021
    Primary completion :
    08/01/2024
    Completion :
    08/01/2025
    BRCA1 • BRCA2 • HRD • CDK12 • CHEK2 • RAD51B • BRIP1 • RAD51C • RAD51D • CHEK1 • BARD1 • RAD54L • FANCL • PPP2R2A • FANCI
    |
    BRCA1 mutation • HRD • ATM mutation • PALB2 mutation • CHEK2 mutation • BRIP1 mutation • HRD + BRCA1 mutation • RAD51C mutation • RAD51D mutation • RAD51B mutation • BARD1 mutation • RAD54L mutation • FANCI mutation • RAD51 mutation
    |
    Zejula (niraparib) • Jemperli (dostarlimab-gxly)
    Niraparib for the Treatment of Leiomyosarcoma (NCI-2021-12582) (NCT05174455)
    Phase 2
    David Liebner, MD
    Withdrawn
    Last update posted :
    09/18/2023
    Initiation :
    12/01/2023
    Primary completion :
    12/31/2024
    Completion :
    12/31/2025
    BRCA1 • BRCA2 • RAD51 • RAD51B • BRIP1 • RAD51C • RAD51D • BARD1
    |
    BRCA1 mutation • PALB2 mutation • BRIP1 mutation • RAD51C mutation • RAD51D mutation • RAD51B mutation • BARD1 mutation
    |
    Zejula (niraparib)
    M6620 (VX-970) in Selected Solid Tumors (NCT03718091)
    Phase 2
    Massachusetts General Hospital
    Completed
    Last update posted :
    07/07/2023
    Initiation :
    01/08/2019
    Primary completion :
    06/01/2020
    Completion :
    07/08/2020
    BRCA1 • BRCA2 • MYC • ATM • ARID1A • CCNE1 • CDK12 • FBXW7 • ATRX • CHEK2 • FANCA • RAD51B • BRIP1 • RAD51C • RAD51D • BARD1 • NBN • FANCF • FANCM • FANCE • FANCC
    |
    BRCA2 mutation • BRCA1 mutation • ATM mutation • ARID1A mutation • MYC amplification • CCNE1 amplification • CDK12 mutation • ATRX mutation • CHEK2 mutation • FBXW7 mutation • BRIP1 mutation • RAD51C mutation • FANCA mutation • RAD51D mutation • RAD51B mutation • BARD1 mutation • FANCF mutation • MRE11A mutation • NBN mutation • FANCM mutation
    |
    berzosertib (M6620)
    The Study of Olaparib Combined With Abiraterone and Prednisone in mHSPC Patients With HRR Gene Mutation (PROact) (NCT05167175)
    Phase 2
    Hongqian Guo
    Recruiting
    Last update posted :
    10/25/2022
    Initiation :
    03/01/2022
    Primary completion :
    12/01/2024
    Completion :
    12/01/2024
    BRCA1 • BRCA2 • HRD • CDK12 • CHEK2 • RAD51B • BRIP1 • RAD51C • RAD51D • CHEK1 • BARD1 • RAD54L • FANCL
    |
    PALB2 mutation • CDK12 mutation • CHEK2 mutation • BRIP1 mutation • RAD51D mutation • RAD51B mutation • BARD1 mutation • RAD54L mutation
    |
    Lynparza (olaparib) • abiraterone acetate • prednisone
    To Assess the Efficacy and Safety of Olaparib Maintenance Monotherapy in the Treatment of Ovarian Cancer (ORZORA) (NCT02476968)
    Phase 4
    AstraZeneca
    Completed
    Last update posted :
    09/10/2022
    Initiation :
    09/28/2015
    Primary completion :
    04/17/2020
    Completion :
    12/17/2021
    BRCA1 • BRCA2 • CDK12 • BRCA • MUC16 • CHEK2 • RAD51B • BRIP1 • RAD51C • CHEK1 • RAD54L • FANCL • PPP2R2A
    |
    BRCA2 mutation • BRCA1 mutation • CHEK2 mutation • RAD51B mutation • BARD1 mutation • BRCA mutation
    |
    Lynparza (olaparib)
    The Study of Olaparib in Newly Diagnosed mCRPC Patients With HRR Gene Mutation (PROspect) (NCT05262608)
    Phase 2
    Sun Yat-Sen Memorial Hospital of Sun Yat-Sen Un...
    Recruiting
    Last update posted :
    03/02/2022
    Initiation :
    12/07/2021
    Primary completion :
    02/26/2024
    Completion :
    04/26/2024
    BRCA1 • BRCA2 • HRD • CDK12 • CHEK2 • RAD51B • BRIP1 • RAD51C • RAD51D • CHEK1 • BARD1 • RAD54L • FANCL
    |
    PALB2 mutation • CDK12 mutation • CHEK2 mutation • BRIP1 mutation • RAD51D mutation • RAD51B mutation • BARD1 mutation • RAD54L mutation
    |
    Lynparza (olaparib)
    Circulating Tumor DNA (ctDNA) Monitoring in the Assessment and Prediction of the Efficacy of PARP Inhibitors (PARPi) (NCT05116579)
    Phase N/A
    Sun Yat-sen University
    Recruiting
    Last update posted :
    11/11/2021
    Initiation :
    10/31/2021
    Primary completion :
    03/31/2023
    Completion :
    08/31/2023
    BRCA1 • BRCA2 • CDK12 • CHEK2 • RAD51B • BRIP1 • RAD51C • RAD51D • CHEK1 • BARD1 • RAD54L • FANCL • PPP2R2A
    |
    BRCA2 mutation • BRCA1 mutation • ATM mutation • PALB2 mutation • CDK12 mutation • CHEK2 mutation • BRIP1 mutation • RAD51C mutation • RAD51D mutation • RAD51B mutation • BARD1 mutation • CHEK1 mutation • RAD54L mutation • BRCA1 mutation + ATM mutation • CHEK1 expression
    Pembrolizumab, Olaparib, Recurrent/Advanced Gastric and Gastro-esophageal Junction(GEJ) Cancer With HRR Mutation and MSS (NCT04592211)
    Phase 1/2
    Yonsei University
    Not yet recruiting
    Last update posted :
    08/31/2021
    Initiation :
    10/01/2021
    Primary completion :
    12/31/2022
    Completion :
    05/31/2023
    HER-2 • BRCA1 • BRCA2 • HRD • MLH1 • MSH6 • MSH2 • CDK12 • CHEK2 • RAD51B • BRIP1 • RAD51C • RAD51D • CHEK1 • BARD1 • RAD54L • FANCL • PPP2R2A
    |
    HER-2 positive • BRCA2 mutation • BRCA1 mutation • ATM mutation • PALB2 mutation • CDK12 mutation • CHEK2 mutation • BRIP1 mutation • RAD51C mutation • RAD51D mutation • RAD51B mutation • BARD1 mutation • CHEK1 mutation • CHEK1 expression
    |
    Keytruda (pembrolizumab) • Lynparza (olaparib) • paclitaxel
    Olaparib Monotherapy in Relapsed Small Cell Lung Cancer Patients With HR Pathway Gene Mutations Not Limited to BRCA 1/2 Mutations, ATM Deficiency or MRE11A Mutations (SUKSES-B) (NCT03009682)
    Phase 2
    Samsung Medical Center
    Completed
    Last update posted :
    02/18/2021
    Initiation :
    08/01/2016
    Primary completion :
    01/01/2021
    Completion :
    01/01/2021
    BRCA1 • BRCA2 • ATM • RAD51 • RAD51B • RAD51C • RAD50 • NBN • RAD54L • WRN • RAD52 • RECQL5 • RECQL • RECQL4 • RPA1
    |
    BRCA2 mutation • BRCA1 mutation • RAD51C mutation • RAD51D mutation • RAD50 mutation • RAD51B mutation • BLM mutation • MRE11A mutation • RAD54L mutation • NBN mutation • WRN mutation • RAD52 mutation • RECQL mutation • RECQL4 mutation • RECQL5 mutation • RPA1 mutation
    |
    Lynparza (olaparib)